Apollomics Inc., a biopharmaceutical company, has submitted a request to the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-3. The request, filed on April 22, 2024, seeks to have the Registration Statement declared effective at 5:00 p.m. Washington, D.C. time on April 24, 2024, or as soon as possible thereafter. This filing follows the initial submission of the Registration Statement on April 1, 2024. Apollomics has engaged Daniel Nussen of White & Case LLP to handle any inquiries and to be notified upon the approval of the acceleration request.

Apollomics Inc., a biopharmaceutical company, has submitted a request to the Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form F-3. The request, filed on April 22, 2024, seeks to have the Registration Statement declared effective at 5:00 p.m. Washington, D.C. time on April 24, 2024, or as soon as possible thereafter. This filing follows the initial submission of the Registration Statement on April 1, 2024. Apollomics has engaged Daniel Nussen of White & Case LLP to handle any inquiries and to be notified upon the approval of the acceleration request.